NMN (Nicotinamide Mononucleotide)
Direct precursor to NAD+ that may restore age-related NAD+ decline and support metabolic health and longevity.
Evidence Summary
Strong preclinical evidence. Human trials show improved insulin sensitivity and muscle function. Long-term outcomes still being studied. David Sinclair research widely cited. UPDATE (August 2026): A Nature Aging 2026 meta-analysis of more than 15,000 human DNA methylation profiles across 17 tissues (Jacques et al., with Horvath, Gladyshev and Teschendorff) used network analysis to separate tightly connected age-associated gene clusters that beneficial interventions do NOT move from a more modifiable cluster linked to NAD+ metabolism - the authors frame this as supporting NAD+ as a candidate therapeutic node in aging. This is meaningful as network-level evidence that NAD+ metabolism sits in an addressable part of the aging epigenome. It is NOT evidence that NMN or any NAD+ precursor supplement improves human aging outcomes; the analysis is cross-sectional and descriptive, with no supplementation arm. Separately, a peer-reviewed systematic review of 27 human nutrition trials (Ageing Research Reviews 2026) found that dietary supplement evidence for moving cellular-senescence biomarkers remains limited and heterogeneous. UPDATE (August 9, 2026): Two peer-reviewed papers this cycle bear on the sirtuin/NAD rationale, and both cut against over-reading it. (1) Nature Aging 2026 (Mu, Barthez et al.; D. Chen, Netea and Verdin labs) shows the mitochondrial deacetylase SIRT3 — highly expressed in hematopoietic stem cells and lost with age — suppresses an HSC response to aging that installs maladaptive trained immunity in myeloid progeny; HSC-specific SIRT3 overexpression improved HSC function and attenuated age-related declines in cognition and motility in distant tissues. This is a genuinely important relocation of inflammaging upstream to a trained stem-cell compartment, but SIRT3 was raised by transgenic overexpression in mice. There is no demonstration that NMN, NR or any NAD+ precursor raises HSC SIRT3 activity or reproduces any part of this phenotype. (2) Nature Aging 2026 (Cole, Buj et al.) identifies fructose as a metabolic component of the chemotherapy-induced SASP that drives ovarian-cancer cell detachment and metastatic dissemination specifically through inhibition of an NAD-SIRT-SREBP axis. That places NAD-sirtuin signalling inside a pro-dissemination pathway in an oncology context — preclinical and model-specific, but a reason for caution rather than confidence about NAD+ loading in patients with active or recent malignancy. UPDATE (September 20, 2026): A peer-reviewed measurement result that directly affects how NMN response is monitored. Nature Metabolism 2026;8:1282-1290 (Tretowicz, Schomakers et al.; Houtkooper lab, Amsterdam UMC) quantified NAD+ across seven independent human cohorts with a rigorously validated UHPLC-high-resolution MS method designed to account for real-world analytical variability, and found whole-blood NAD+ STABLE with chronological age and UNCHANGED by lifestyle interventions - while responding as expected to nicotinamide riboside supplementation. The authors conclude that blood NAD+ is not a useful biomarker of ageing or lifestyle, and that much of the previously reported age-related decline is plausibly assay variability. Scope this carefully: the paper does not refute tissue or intracellular NAD+ decline, does not test NMN specifically, and does not evaluate any clinical outcome of precursor supplementation - the mechanistic NAD+ rationale summarised above is untouched. What it does remove is the common practice of using a blood NAD+ level as a biological-age readout or as proof that a precursor is working; a supplement-induced rise demonstrates absorption, not benefit. Balancing this, GeroScience 2026 (Itabashi Longitudinal Study on Aging, 16 Sept 2026) reported that among 529 community-dwelling Japanese adults aged 65+, the 32 (6.0%) meeting revised J-CHS frailty criteria had lower median whole-blood NAD+ than non-frail participants, robust to adjustment for age, sex and fasting time and to spline, Firth penalised-likelihood and haematological sensitivity analyses. This is the clearest human association to date between circulating NAD+ and a functional outcome, and it is a legitimate reason to keep the axis under study - but it is cross-sectional with only 32 frail participants, reverse causation is unaddressed, and it tests no supplement. Human NMN evidence remains limited to short-duration surrogate endpoints. UPDATE (November 14, 2026): New clinical-outcome meta-analyses sharpen the human picture, and both are modest. (1) A 2026 systematic review and meta-analysis in Nutrients (Zhang M et al.; 10 RCTs, 349 participants with elevated blood pressure) found oral NMN associated with a small but statistically significant reduction in resting diastolic blood pressure versus placebo (weighted mean difference -2.15 mmHg, 95% CI -3.68 to -0.61); the pooled effect on systolic blood pressure was not significant overall but reached significance in adults aged 60 and older (-3.94 mmHg, 95% CI -7.06 to -0.82). (2) A separate 2026 Nutrients safety meta-analysis (Yang W et al.; 15 trials, doses 250-2000 mg/day for 14 days to 24 weeks) found NMN well tolerated, with no increase in overall, serious, or system-specific adverse events and no elevation of ALT or AST; it found no significant effect on body weight, BMI, fasting glucose, HbA1c, or lipids, with only a slight diastolic blood pressure reduction and a non-significant downward trend in HOMA-IR. (3) A 2024 post-hoc dose-response analysis (Kuerec/Maier et al., Mechanisms of Ageing and Development) of the 80-person 300/600/900 mg trial confirmed a dose-dependent rise in blood NAD+ that correlated with 6-minute-walk and SF-36 gains, but with very high between-person variability. Net: short-term oral NMN appears safe and may modestly lower blood pressure - most clearly diastolic, and systolic mainly in older adults - but broad metabolic benefits are not established and all endpoints remain short-duration surrogates. This is not a treatment for hypertension or any disease.
Evidence Scale
Mechanism of Action
Converted to NAD+ via NMN adenylyltransferases. Supports sirtuin activation, DNA repair (PARP), mitochondrial function, and cellular energy metabolism.
Who Is This For?
Age-related decline, metabolic dysfunction, longevity optimization. NAD+ levels decrease significantly with age.
Protocol & Dosing
Dose
250-1000mg daily. Common: 500mg morning.
Frequency
Daily
Duration
Ongoing
Protocol Summary
Oral supplementation, typically morning. Sublingual may improve absorption. Consider with TMG for methyl group support.
Latest Evidence
2026: new RCT meta-analyses on oral NMN
Two 2026 meta-analyses in Nutrients now summarise the human trial evidence. Across 10 randomized controlled trials in 349 adults with elevated blood pressure, oral NMN was associated with a small but statistically significant drop in resting diastolic blood pressure versus placebo (-2.15 mmHg, 95% CI -3.68 to -0.61); the effect on systolic blood pressure was not significant overall but reached significance in adults aged 60 and older (-3.94 mmHg, 95% CI -7.06 to -0.82). A companion safety meta-analysis of 15 trials (250-2000 mg/day, 2-24 weeks) found NMN well tolerated, with no increase in serious adverse events and no rise in liver enzymes, but no meaningful change in weight, glucose, HbA1c, or lipids. An earlier dose-response analysis confirmed a dose-dependent rise in blood NAD+ that tracked with 6-minute-walk and quality-of-life gains, albeit with wide person-to-person variability.
These are modest, short-duration surrogate endpoints, not evidence that NMN treats hypertension or any disease, and broad metabolic benefit has not been established. As noted in the record, a blood NAD+ rise reflects absorption rather than proven benefit. Discuss supplementation with your physician, particularly if you have a history of cancer or take other medications. Educational information, not medical advice.
Pooled RCTs · n=349 · 2026 meta-analysis
Modest blood-pressure reduction with oral NMN
Source: Effects of nicotinamide mononucleotide supplementation on blood pressure - a systematic review and meta-analysis of randomized controlled trials, Nutrients 2026 (Zhang M et al.; 10 RCTs, 349 adults with elevated blood pressure). Bars show the pooled mean difference vs. placebo; 95% confidence intervals appear on hover. Pooled systolic BP across all adults was not statistically significant - the systolic effect shown is the prespecified subgroup aged 60 and older. These are modest, short-term surrogate findings and not a treatment for hypertension.
Related on Peak Human
NMN Supplement Guide
Forms, dosing, and quality considerations for NMN.
Nicotinamide Riboside (NR)
The other major NAD+ precursor, compared.
NAD+ IV Therapy
Intravenous route for raising NAD+.
Longevity
Physician-guided healthy-aging protocols.
Shop Supplements
Practitioner-selected supplement options.
Longevity Research Insider
Weekly review of new longevity research.
Key references: NMN & blood pressure: systematic review & meta-analysis of RCTs - Nutrients (2026) · Safety & metabolism-related outcomes of oral NMN: meta-analysis - Nutrients (2026) · Dose-response NMN & NAD concentration - Mech. Ageing Dev. (2024)
Interactions & Precautions
Contraindications
- None established
Potential Risks
- •Limited long-term human data
- •Quality control concerns
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Combine with TMG (betaine) to support methylation. Morning dosing preferred. Consider NAD+ testing to track. Quality varies significantly between brands. Updated August 2026: The 2026 cross-tissue methylation atlas gives a defensible mechanistic rationale for interest in NAD+ metabolism, and patients will cite it. Be precise about what it does and does not show - it identifies NAD+-linked methylation as a modifiable module in a network analysis; it does not test supplementation and reports no clinical outcome. Human NMN trial evidence remains limited to short-duration surrogate endpoints. Continue to set expectations accordingly rather than upgrading the recommendation on the strength of this paper. Updated August 9, 2026: Expect patients to cite the 2026 SIRT3 stem-cell paper as support for NAD+ precursors. It is not. SIRT3 was manipulated genetically in mice; no supplement has been shown to raise HSC SIRT3 activity. Separately, the 2026 SASP-fructose work situates the NAD-SIRT-SREBP axis inside a pathway promoting metastatic dissemination in chemotherapy-treated ovarian cancer models — preclinical, but enough to warrant a conservative stance on NAD+ loading in patients with active malignancy or on recent cytotoxic therapy, and to prompt an explicit oncology-history question before starting. Human NMN evidence remains short-duration surrogate endpoints. Updated September 20, 2026: A specific change to monitoring practice. The prior note here recommended considering NAD+ testing to track response - that recommendation should now be withdrawn. Nature Metabolism 2026 (seven human cohorts, validated UHPLC-HRMS) found whole-blood NAD+ does not decline with age and does not move with lifestyle, moving only with precursor supplementation. So a blood NAD+ level cannot serve as a biological-age readout, cannot establish that a patient "needs" NMN, and a post-supplement rise confirms absorption rather than benefit. If tracking is wanted, use functional and clinical endpoints, not a blood NAD+ number. Two further points for consultation: (1) patients who have purchased consumer NAD+ testing should be told plainly that the assay has not been validated as an aging biomarker and that reported age-related declines may largely reflect analytical variability; (2) the GeroScience 2026 frailty association (lower whole-blood NAD+ in the 6% who were frail, n=529) will be cited as a counterargument - it is real and worth knowing, but it is cross-sectional, reverse causation is untested, and it studied no supplement. Continue to combine with TMG for methylation support, prefer morning dosing, and keep expectations anchored to short-duration surrogate-endpoint evidence. Updated November 14, 2026: Two 2026 meta-analyses now bound the near-term clinical expectation. Tolerability looks good across 250-2000 mg/day with no signal of liver-enzyme or serious adverse-event elevation, which supports a conservative trial in motivated patients. Efficacy is modest and mostly vascular: roughly a 2 mmHg diastolic reduction overall and roughly a 4 mmHg systolic reduction in adults 60+, with no reliable effect on weight, glucose, HbA1c or lipids. Frame NMN as a low-risk, modest-signal adjunct - not a blood-pressure therapy and not a substitute for established cardiovascular and metabolic care. Continue to anchor expectations to short-duration surrogate endpoints, keep the morning-dosing and TMG guidance, and (per the September note) do not rely on blood NAD+ levels to confirm benefit. Educational information, not medical advice.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
$$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
